Eisai CoESALF 74 ROC (Joel Greenblatt) % is -6.55% as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $34.94 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 977 Drug Manufacturers companies, Eisai Co ranks better than 57.52% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Eisai Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -6.55%.
The historical rank and industry rank for Eisai Co's ROC (Joel Greenblatt) % or its related term are showing as below:
ESALF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 15.36 Med: 27.16 Max: 81.1
Current: 15.36
During the past 13 years, Eisai Co's highest ROC (Joel Greenblatt) % was 81.10%. The lowest was 15.36%. And the median was 27.16%.
ESALF's ROC (Joel Greenblatt) % is ranked better than 57.52% of 977
companies
in the Drug Manufacturers industry
Industry Median: 11.37
vs ESALF: 15.36
Eisai Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -9.60% per year.
Eisai Co (OTCPK:ESALF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for Eisai Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESALF vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Eisai Co's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -6.55% mean?
Eisai Co (ESALF) has a ROC (Joel Greenblatt) % of -6.55% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Eisai Co and its competitors. Over the past decade, Eisai Co's ROC (Joel Greenblatt) % has ranged from 15.36 to 81.10. According to the industry distribution chart, Eisai Co ranks #415 out of 977 companies in the Drug Manufacturers industry, placing it in the top 42.5%.
Is Eisai Co's ROC (Joel Greenblatt) % too high?
Eisai Co's current ROC (Joel Greenblatt) % is -6.55%. Over the past 10 years, this metric has ranged from a low of 15.36 to a high of 81.10. Based on the distribution chart, Eisai Co ranks #415 out of 977 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #415 out of 977 companies for ROC (Joel Greenblatt) %. This puts Eisai Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.37. Historically, Eisai Co's own ROC (Joel Greenblatt) % has ranged from 15.36 to 81.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.37, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current ROC (Joel Greenblatt) % is -6.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $34.94, compared to a current price of $25.00 — trading 28.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is -6.55%. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Eisai Co (ESALF), the current ROC (Joel Greenblatt) % is -6.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 28.4% below its estimated GF Value™ of $34.94.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for ESALF:
ROC (Joel Greenblatt) %: -6.55%
GF Value™: $34.94 vs. price of $25.00 (28.4% below fair value)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for ESALF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
